SteriPlas proven to lower antibiotic usage

“Patients in the CAP treatment group were more likely to achieve reduction in wound size (71% vs 37.5%), resolution of wounds infection (71% vs 25%) and lower overall use of antibiotics (57% vs 100%).”

Our Health Economics data further demonstrates why the SteriPlas Premium Cold Plasma is the leading medical device for chronic diabetic foot ulcers. Continuing to relieve the cost burden associated to hospitals dealing with infection, the SteriPlas has been transforming how modern medicine works. Many users have changed their treatment guidelines to incorporate the SteriPlas and replace existing therapies that failed to work as well as the SteriPlas does.

For more information about our strong clinical efficacy and Health Economics, contact us at info@adtecplasma.com